2025-05-02
2025-04-28
2025-04-26
2025-04-09
2025-04-03
2025-03-27
信达PCSK9抗体Tafolecimab I/II期研究结果在...
2025-03-25
2025-03-23
2025-03-18
2025-03-18
2025-03-12
信达已入局,罗氏2:1 TCB--CD20xCD3双抗获...
2025-03-11
2025-03-08
2025-03-01
2025-02-28
2025-02-22
2025-02-13
2025-02-10
2025-02-04
2025-02-02
2025-01-27
2025-01-25
2025-01-23
2025-01-21
2025-01-13
2025-01-09
2025-01-03
2024-12-27
2024-12-25
2024-12-10
2024-12-09
2024-12-06
2024-12-05
2024-12-04
2024-11-21
2024-11-19
2024-11-18
2024-11-13
2024-11-13
2024-11-12
2024-11-12
2024-11-01
2024-10-31
2024-10-28
2024-10-18
2024-10-15
2024-10-11
2024-10-07
2024-09-18
2024-09-18
2024-09-17
2024-09-16
2024-09-12
2024-09-09
2024-09-08
2024-09-05
2024-09-03
2024-09-02
2024-09-01
2024-08-30
2024-08-27
2024-08-27
2024-08-25
2024-08-17
2024-08-17
2024-08-09
2024-08-06
2024-08-01
2024-07-29
2024-07-28
2024-07-27
2024-07-26
2024-07-25
2024-07-25
2024-07-24
2024-07-21
2024-07-19
2024-07-17
2024-07-16
2024-07-04
2024-07-02
2024-07-01
2024-06-29
2024-06-27
2024-06-27
2024-06-27
2024-06-21
2024-06-17
2024-06-16
2024-06-06
2024-05-28
2024-05-23
2024-05-23
2024-05-21
2024-05-19
2024-05-18
2024-05-13
2024-05-13
2024-05-12
2024-05-11
2024-05-11
2024-04-28
2024-04-27
2024-04-27
2024-04-27
2024-04-25
2024-04-25
2024-04-24
2024-04-23
2024-04-20
2024-04-20
2024-04-20
2024-04-18
2024-04-17
2024-04-14
2024-04-13
2024-04-12
2024-04-12
2024-04-12
2024-04-10